Portfolio of Gene Editing (CRISPR) Stocks

Here are 4 gene editing stocks that use CRISPR technology.


4 Portfolio of Gene Editing (CRISPR) Stocks

Stock Returns & Price Chart

Symbol

Recent Prices &
Annualized Return

Crispr TherapeuticsCRSP
Editas MedicineEDIT
Intellia TherapeuticsNTLA
Vertex PharmaceuticalsVRTX
Price data from Quandl as of most recent close.


4 Portfolio of Gene Editing (CRISPR) Stocks

Stock Returns & Price Chart

Symbol

Recent Dividends

Crispr TherapeuticsCRSP
Editas MedicineEDIT
Intellia TherapeuticsNTLA
Vertex PharmaceuticalsVRTX
Dividend chart data from Quandl as of today.


To inspect the performance of the Portfolio of Gene Editing (CRISPR) Stocks portfolio, see the chart below. Portfolio values are computed using monthly closes for stocks from Quandl.

All 4 stocks are included in the portfolio computations. The current value of the portfolio assumes that $2,500.00 was invested (total of $10,000) in each stock at its closing monthly price for the first date shown on the portfolio value chart below. All prices are adjusted for splits and dividends.

The current value of a $10,000 investment is $14,858. The percent return is 48.58%. The annualized return is 21.89%.




Return Summary for Portfolio of Gene Editing (CRISPR) Stocks
Start DateNov-30-2017
Start Investment$10,000.00
End DateNov-18-2019
Current Value of Investment$14,858.32
Total Return48.58%
Annualized Return21.89%
Min DateNov-30-2017
Min Price$10,000.00
Max DateMay-31-2018
Max Price$18,066.88
# Values25
Number Returns300
Number Profitable Returns140
Percent Profitable Returns46.67%
Number Unprofitable Returns160
Percent Unprofitable Returns53.33%
Profitable to Unprofitable Returns Ratio0.88



NOTE: The stocks included in the tables and chart are representative of the industry. They are not recommendations.


Related Portfolios

Portfolio of Biotech Stocks

Portfolio of Genetic Testing Stocks

Portfolio of Genomics Stocks

Portfolio of Stem Cell Stocks